Virus-Specific Lymphocyte Enrichment for Scalable Allogeneic CAR-T
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional CAR-T cell therapies for cancer treatment are limited by autologous features, manufacturing issues, high costs, and heterogeneity, making them unsuitable for all patients and posing quality concerns.
Innovation Solution
A method to enrich and activate Vβ17+CD8+ T cells using a M1 peptide from human influenza A virus and IL-2, followed by culturing these cells ex vivo to increase their percentage and introduce a chimeric antigen receptor (CAR) for targeted cancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CAR-T cell therapy uses autologous T cells collected from each patient, then the treatment is personalized and reduces rejection risk, but the manufacturing process becomes complex, time-consuming, and expensive
Solution Approach 1:
The patent uses allogeneic T cells as a standardized 'copy' or template that can be manufactured once and used for multiple patients, eliminating the need for complex individualized manufacturing processes while maintaining therapeutic efficacy through CAR modification
Solution Approach 2:
The patent separates the T cell collection step from the CAR therapy delivery step by using pre-collected allogeneic T cells that are then genetically modified with CAR constructs, simplifying the overall manufacturing process into distinct modular steps
2Reliability
If conventional CAR-T cell therapy processes are used, then clinical grade cells can be produced, but manufacturing failures, time delays, and insufficient cell expansion occur
Solution Approach 1:
The patent performs preliminary T cell collection and expansion from healthy donors before patient treatment is needed, creating a ready supply of qualified T cells that can be rapidly processed with CAR constructs when clinical need arises, eliminating manufacturing delays
Solution Approach 2:
The patent optimizes culture conditions including IL-2 concentration, culture duration, and cell density parameters to achieve reliable expansion of allogeneic T cells while maintaining clinical grade quality standards
3Ease of manufacture
If allogeneic T cells from healthy donors are used, then T cell collection is feasible for all patients and manufacturing is simplified, but the initial percentage of target T cells is low
Solution Approach 1:
The patent employs continuous culture expansion of allogeneic T cells over multiple days with optimized media conditions, progressively increasing the quantity and percentage of target T cells from initial low levels to therapeutic concentrations
Solution Approach 2:
The patent uses cytokines such as IL-2 as intermediary substances that mediate T cell proliferation and differentiation, enabling the expansion of target T cell populations from low initial percentages to sufficient therapeutic levels
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly enhances the percentage of Vβ17+CD8+ T cells, enabling efficient and targeted cancer cell elimination with reduced manufacturing challenges and costs, suitable for a broader patient population.
Implementation Method 1
contacting a M1 peptide derived from human influenza A virus (M158-66) with a population of cells comprising T cells
Implementation Method 2
the method further comprises contacting IL-2 with the population of the cells comprising the T cells
Data Source
AI summary
A method for activating or enriching Vβ17+CD8+ T cells, comprising contacting a M1 peptide derived from human influenza A virus (M158-66) with a population of cells comprising T cells.